138 related articles for article (PubMed ID: 22858075)
1. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.
El-Shitany NA; Tolba OA; El-Shanshory MR; El-Hawary EE
J Card Fail; 2012 Aug; 18(8):607-13. PubMed ID: 22858075
[TBL] [Abstract][Full Text] [Related]
2. Preventive role of carvedilol in adriamycin-induced cardiomyopathy.
Jhorawat R; Kumari S; Varma SC; Rohit MK; Narula N; Suri V; Malhotra P; Jain S
Indian J Med Res; 2016 Nov; 144(5):725-729. PubMed ID: 28361826
[TBL] [Abstract][Full Text] [Related]
3. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.
Elitok A; Oz F; Cizgici AY; Kilic L; Ciftci R; Sen F; Bugra Z; Mercanoglu F; Oncul A; Oflaz H
Cardiol J; 2014; 21(5):509-15. PubMed ID: 24142687
[TBL] [Abstract][Full Text] [Related]
4. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
[TBL] [Abstract][Full Text] [Related]
5. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
Jovanovic D; Jovovic D; Mihailovic-Stanojevic N; Miloradovic Z; Naumovic R; Dimitrijevic J; Maksic N; Djukanovic L
Biomed Pharmacother; 2009 Sep; 63(8):571-6. PubMed ID: 19013753
[TBL] [Abstract][Full Text] [Related]
6. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
7. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
[TBL] [Abstract][Full Text] [Related]
9. Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy.
Jovanovic D; Jovovic D; Mihailovic-Stanojevic N; Miloradovic Z; Dimitrijevic J; Maksic N; Djukanovic L
Clin Nephrol; 2005 Jun; 63(6):446-53. PubMed ID: 15960146
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy.
Cheung YF; Hong WJ; Chan GC; Wong SJ; Ha SY
Heart; 2010 Jul; 96(14):1137-41. PubMed ID: 20511624
[TBL] [Abstract][Full Text] [Related]
11. Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia.
Hagag AA; Badraia IM; El-Shehaby WA; Mabrouk MM
J Oncol Pharm Pract; 2020 Sep; 26(6):1397-1406. PubMed ID: 31964219
[TBL] [Abstract][Full Text] [Related]
12. Treatment of dilated cardiomyopathy with carvedilol in children.
Erdoğan I; Ozer S; Karagöz T; Celiker A; Ozkutlu S; Alehan D
Turk J Pediatr; 2009; 51(4):354-60. PubMed ID: 19950843
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin).
Machado V; Cabral A; Monteiro P; Gonçalves L; Providência LA
Rev Port Cardiol; 2008 Oct; 27(10):1277-96. PubMed ID: 19178029
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.
Barone FC; Willette RN; Nelson AH; Ohlstein EH; Brooks DP; Coatney RW
Pharmacology; 2007; 80(2-3):166-76. PubMed ID: 17551266
[TBL] [Abstract][Full Text] [Related]
15. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).
Bosch X; Rovira M; Sitges M; Domènech A; Ortiz-Pérez JT; de Caralt TM; Morales-Ruiz M; Perea RJ; Monzó M; Esteve J
J Am Coll Cardiol; 2013 Jun; 61(23):2355-62. PubMed ID: 23583763
[TBL] [Abstract][Full Text] [Related]
16. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats.
El-Shitany NA; El-Haggar S; El-desoky K
Food Chem Toxicol; 2008 Jul; 46(7):2422-8. PubMed ID: 18487002
[TBL] [Abstract][Full Text] [Related]
17. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
Bergström A; Andersson B; Edner M; Nylander E; Persson H; Dahlström U
Eur J Heart Fail; 2004 Jun; 6(4):453-61. PubMed ID: 15182771
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.
Hayakawa H; Komada Y; Hirayama M; Hori H; Ito M; Sakurai M
Med Pediatr Oncol; 2001 Jul; 37(1):4-9. PubMed ID: 11466716
[TBL] [Abstract][Full Text] [Related]
19. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy.
Doughty RN; Whalley GA; Walsh HA; Gamble GD; López-Sendón J; Sharpe N;
Circulation; 2004 Jan; 109(2):201-6. PubMed ID: 14707020
[TBL] [Abstract][Full Text] [Related]
20. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
